United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,712,246.04. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $1.78 during trading hours on Thursday, reaching $547.69. The company had a trading volume of 411,933 shares, compared to its average volume of 479,197. The business’s 50 day moving average price is $567.74 and its 200-day moving average price is $518.04. The firm has a market cap of $23.25 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the business earned $6.63 EPS. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, analysts expect that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Avoro Capital Advisors LLC increased its stake in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its holdings in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Janus Henderson Group PLC grew its holdings in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics during the third quarter worth $317,617,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. Bank of America raised their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.